‘Shallowing' is a popular bedroom trend that men and women across the country are trying — and loving
'Shallowing' is a popular sex trend that has taken off — and gotten women off — within the last year.
It's nicknamed 'outercourse' because it involves light sexual play of the entrance to the vagina and slightly inside — without deeper penetration.
Shallowing was only formally named a few years ago, and it's become increasingly popular — especially since sexual wellness brand LELO listed it as one of the top sex trends for 2024. And it seems to still be going strong.
This sexual fun is not just a spicy trend people are taking part in — solo or with a partner — a survey has proven it to be pleasurable for most women.
In a 2021 survey of over 4,000 women conducted by the Indiana University School of Medicine and OMGYES, it was discovered that almost 84% of US women between the ages of 18 and 93 found increased pleasure from this outercourse play.
While some people are having some shallow fun — others are curious about experimenting with different sex positions to spice things up in the bedroom.
A team of FetishFinder researchers looked at Google search patterns to uncover which sex positions people are most intrigued by.
And it seems missionary is a snooze fest these days because the 'bear hug' position took the cake as the most searched.
This position involves doing the deed while hugging each other like a bear standing up. It certainly caught people's attention because it saw a 623% spike in searches within the last year.
Other highly searched positions included the 'filthy Sanchez' — which is more on the crude side of things, as it involves smearing bodily fluids on a person's upper lip.
The third most Google-searched position is the 'anvil' — which requires one partner to lie on their back, legs lifted overhead, while the other person and kneeling, does what you'd imagine they'd be doing during frisky time.
The anvil saw a 275% increase in searches.
And it seems when people aren't searching for new ways to position their bodies in the bedroom — they're also turning to Chat GPT to inquire about health, sex and pleasure.
'It's important that anyone with questions about sex and pleasure can receive answers from trusted sources,' said Verena Singmann, spokesperson for We-Vibe, a sexual pleasure brand.
'Technology can be a helpful tool when it comes to sex and pleasure, but AI doesn't always know best when it comes to our sexual health and wellbeing.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
17-06-2025
- New York Post
Nearly a quarter of Americans want a break from sex — a new study shows why
A quarter of Americans want a break from sex (24%), according to new research. A survey explored how 2,000 adults are viewing intimacy in today's day and age, finding that some of the reasons they gave for wanting a break being 'to learn other forms of intimacy,' 'give the body and mind a chance to catch up' or because they 'want emotional closeness more.' Advertisement Even beyond their personal goals, nearly a third sadly believe romance is dead (30%), believing that real love and romantic gestures are no longer valued today. These ideas have played a role in half of respondents previously taking an extended break from having sex (52%) for an average of six months. 7 New research revealed that 24% of Americans want a break from sex. Louis Beauchet – Conducted by Talker Research in partnership with LELO, the survey found that of those who took a sex sabbatical, 53% said that it made them miss and appreciate it more, while just 11% said it had the opposite effect on them. Advertisement Many have found themselves enjoying singledom, with 69% of those who aren't in relationships content with being single and only 21% actively looking for a relationship. 7 Most believe that believing that real love and romantic gestures are no longer valued today. SWNY Those who aren't looking for relationships said it's because they are 'very comfortable with [my] life at the moment, ' 'waiting for the right one to come to me' or simply because they are 'satisfied with [my] single life.' With that in mind, 55% of singles would rather fall in love with life than with someone else next. Advertisement Respondents are also looking to be grounded more often, as 47% of single Americans agree that relationships tend to be too focused on the far future instead of the now. It doesn't help that half of those surveyed have been in a relationship that was 'ruined' by expectations for what it 'should' be like (49%). 7 For most people, distance makes the heart grow fonder. SWNY 7 Sadly a third of Americans believe romance is dead. SWNY Advertisement As a result, a majority of singles said that a relationship is not what they need right now (59%). 'Slowing down and taking a break from sex can be a healthy and beneficial approach in various situations, whether for personal growth, relationship issues or addressing specific issues,' said Luka Matutinovic, chief marketing officer at LELO. 'A sex break can allow for a reassessment of sexual desires and needs. Moreover, taking a break from the pressure and focus of sex can reset your relationship and facilitate honesty with yourself and each other.' But sex isn't everything: The average person says that just 37% of intimacy has to do with sex, and 57% instead has to do with understanding each other on a personal level. Wanting more than just physicality, three in four express intimacy to their partner in alternate ways (76%). 7 To some, sex isn't everything. SWNY Some of their favorite ways to do so are 'holding hands,' 'kissing and touching' and appreciating small moments together like 'brushing his hair.' Further, four times the percentage of respondents agree that they'd rather have a partner that meets their emotional intimacy needs than their physical intimacy needs. 7 While 47% believe that taking a break from sex is healthy for couples, 44% of those in relationships said that theirs wouldn't last a year without sex. SWNY Advertisement Still, half of Americans acknowledge that sex is necessary for bringing two people closer romantically (54%). While 47% believe that taking a break from sex is healthy for couples, 44% of those in relationships said that theirs wouldn't last a year without sex. The average person believes that couples should have sex three times a week in order to have a 'healthy sex life.' 7 On average, Americans admit they can't go more than five months without kissing or cuddling, and six months with no sex. SWNY Advertisement And when it comes to themselves, on average, Americans admit they can't go more than five months without kissing or cuddling, and six months with no sex. 'Sex and intimacy are distinct, and while they can coexist, they don't need to be synonymous,' said Matutinovic. 'Taking breaks from sex or focusing on other forms of physical intimacy can actually enhance a sex life by reducing pressure and fostering exploration, as well as introducing new additions to your routine, like sex toys, thus bolstering emotional intimacy.' NON-SEXUAL WAYS RESPONDENTS ARE INTIMATE 'Compliments.' ''Cuddling.' 'Giving them a shoulder massage.' 'Kissing and touching.' 'Having uplifting words and encouragement.' 'Cook for them.' 'Buying gifts.' 'Holding hands.' 'Deep spiritual conversation.' 'Brushing his hair.' Advertisement Survey methodology: Talker Research surveyed 2,000 general population Americans; the survey was commissioned by LELO and administered and conducted online by Talker Research between May 23 and May 27, 2025.
Yahoo
10-06-2025
- Yahoo
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program, Indiana University School of Medicine; and Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer, Summit Clinical Research, & Director of the Steatotic Liver Program, North Shore Gastroenterology, Cleveland, OH. The event will highlight results from Galectin's NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin may represent the first potential treatment to address this significant unmet need. A live question and answer session will follow the formal presentations. About Naga P. Chalasani, MD Naga P. Chalasani, MD completed medical school in India before he moved to the US to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology and as Director of Terance Kahn Liver Research Program at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), Associate Dean for Clinical Research (2017-2020) interim Chair of the Department of Medicine (2020-2021) and Vice President for Academic Affairs at Indiana University Health (2022-2024). He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years. He has been continuously funded by the National Institutes of Health (NIH) since 1999 and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He is one of the most published and most cited investigators at Indiana University, with Google Scholar H-Index 120 and 75,000 citations (as of Feb 2025). He is an elected member of the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP) and the National Academy of Medical Sciences – India (2024). He has mentored over 75 undergraduate and graduate students, medical students, sub-specialty trainees, and junior faculty. Twenty of his mentees are recipients of federal funding (K award, U01, R21, R01, DOD, and VA Merit Review). To honor his contributions and mentorship, Naga P Chalasani Endowed Professor in Gastroenterology and Hepatology has been established at Indiana University School of Medicine in October 2022. About Naim Alkhouri, MD, FAASLD, DABOM Naim Alkhouri, MD, FAASLD, DABOM is the Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH. Prior to joining Summit, Dr. Alkhouri served as the Chief Medical Officer and Director of the Steatotic Liver Disease program at Arizona Liver Health in Phoenix, AZ. Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG). Dr. Alkhouri has been published in over 260 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as 'may,' 'estimate,' 'could,' 'expect', 'look forward', 'believe', 'hope' and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not product positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact:Jack Callicutt, Chief Financial Officer(678) 620-3186ir@ Investor Relations Contact:Kevin Gardnerkgardner@ Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor belapectin.
Yahoo
05-06-2025
- Yahoo
‘Shallowing' is a popular bedroom trend that men and women across the country are trying — and loving
'Shallowing' is a popular sex trend that has taken off — and gotten women off — within the last year. It's nicknamed 'outercourse' because it involves light sexual play of the entrance to the vagina and slightly inside — without deeper penetration. Shallowing was only formally named a few years ago, and it's become increasingly popular — especially since sexual wellness brand LELO listed it as one of the top sex trends for 2024. And it seems to still be going strong. This sexual fun is not just a spicy trend people are taking part in — solo or with a partner — a survey has proven it to be pleasurable for most women. In a 2021 survey of over 4,000 women conducted by the Indiana University School of Medicine and OMGYES, it was discovered that almost 84% of US women between the ages of 18 and 93 found increased pleasure from this outercourse play. While some people are having some shallow fun — others are curious about experimenting with different sex positions to spice things up in the bedroom. A team of FetishFinder researchers looked at Google search patterns to uncover which sex positions people are most intrigued by. And it seems missionary is a snooze fest these days because the 'bear hug' position took the cake as the most searched. This position involves doing the deed while hugging each other like a bear standing up. It certainly caught people's attention because it saw a 623% spike in searches within the last year. Other highly searched positions included the 'filthy Sanchez' — which is more on the crude side of things, as it involves smearing bodily fluids on a person's upper lip. The third most Google-searched position is the 'anvil' — which requires one partner to lie on their back, legs lifted overhead, while the other person and kneeling, does what you'd imagine they'd be doing during frisky time. The anvil saw a 275% increase in searches. And it seems when people aren't searching for new ways to position their bodies in the bedroom — they're also turning to Chat GPT to inquire about health, sex and pleasure. 'It's important that anyone with questions about sex and pleasure can receive answers from trusted sources,' said Verena Singmann, spokesperson for We-Vibe, a sexual pleasure brand. 'Technology can be a helpful tool when it comes to sex and pleasure, but AI doesn't always know best when it comes to our sexual health and wellbeing.'
